OncoMatch/Clinical Trials/NCT03755739
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Is NCT03755739 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy for hepatocarcinoma.
Treatment: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy — This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Melanoma
Renal Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Pancreatic Cancer
Ovarian Cancer
Colorectal Cancer
Cervical Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control
Kidney function
Cr ≤ 145.5 umul/L
Liver function
Child-Pugh class A or B/Child score > 7; Albumin > 28 g/L; Total bilirubin < 51 μmol/L
Child-Pugh class A or B/Child score > 7; WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR < 2.3 or PT < 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin > 28 g/L；Total bilirubin < 51 μmol/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify